Eukles Asset Management’s AbbVie ABBV Stock Holding History

Eukles Asset Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-30	Closed	-$4.65K	–	233
2023 Q4	$4.65K	Hold	30	–	–	﹤0.01%	183
2023 Q3	$4.47K	Hold	30	–	–	﹤0.01%	181
2023 Q2	$4.04K	Hold	30	–	–	﹤0.01%	181
2023 Q1	$4.78K	Hold	30	–	–	﹤0.01%	164
2022 Q4	$5K	Hold	30	–	–	﹤0.01%	157
2022 Q3	$4K	Hold	30	–	–	﹤0.01%	161
2022 Q2	$5K	Hold	30	–	–	﹤0.01%	147
2022 Q1	$5K	Sell	30 -84	-74%	-$12.2K	﹤0.01%	155
2021 Q4	$15K	Buy	114 +84	+280%	+$9.92K	0.01%	127
2021 Q3	$3K	Hold	30	–	–	﹤0.01%	177
2021 Q2	$3K	Hold	30	–	–	﹤0.01%	205
2021 Q1	$3K	Buy	+30	New	+$3.21K	﹤0.01%	174

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Eukles Asset Management's ABBV Position: Q1 2024 in Review

Eukles Asset Management sold out of AbbVie (ABBV) in Q1 2024, closing a stake of 30 shares — an estimated $4.65K sold.

Eukles Asset Management first reported a position in ABBV in Q1 2021 and held it in 12 quarters. The position peaked at $15K in Q4 2021. 3,379 funds tracked by Wall St. Rank hold ABBV as of Q1 2024.

Eukles Asset Management reported no remaining AbbVie position as of Q1 2024 after selling out during the quarter.
Eukles Asset Management sold 30 AbbVie shares in Q1 2024, an estimated $4.65K.
Eukles Asset Management first reported a position in AbbVie in Q1 2021 and held it in 12 quarters.
Eukles Asset Management's AbbVie position peaked at $15K in Q4 2021.
3,379 funds tracked by Wall St. Rank held AbbVie as of Q1 2024.

Based on Eukles Asset Management's 13F filing for Q1 2024, filed 13 May 2024.